Senhwa Biosciences launches global study for cancer breakthrough
May 06, 2026 | 09:54
Senhwa Biosciences initiated a global clinical study, aiming for a breakthrough in hard-to-treat cancers by combining CX-5461 and Tislelizumab, potentially offering new therapeutic options for patients.
Mobile Version